Citigroup’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-461,240
| Closed | -$678K | – | 6666 |
|
|
2022
Q2 | $678K | Buy |
461,240
+439,911
| +2,063% | +$323K | ﹤0.01% | 2993 |
|
|
2022
Q1 | $25K | Sell |
21,329
-6,929
| -25% | -$11.3K | ﹤0.01% | 5047 |
|
|
2021
Q4 | $71K | Sell |
28,258
-202,629
| -88% | -$796K | ﹤0.01% | 4914 |
|
|
2021
Q3 | $1.18M | Sell |
230,887
-184,017
| -44% | -$1.12M | ﹤0.01% | 2960 |
|
|
2021
Q2 | $3.45M | Buy |
414,904
+73,211
| +21% | +$617K | ﹤0.01% | 2235 |
|
|
2021
Q1 | $2.98M | Buy |
341,693
+291,514
| +581% | +$3.02M | ﹤0.01% | 2211 |
|
|
2020
Q4 | $545K | Buy |
50,179
+21,175
| +73% | +$261K | ﹤0.01% | 4130 |
|
|
2020
Q3 | $346K | Sell |
29,004
-87,544
| -75% | -$1.17M | ﹤0.01% | 4172 |
|
|
2020
Q2 | $1.87M | Buy |
116,548
+64,764
| +125% | +$1.13M | ﹤0.01% | 2885 |
|
|
2020
Q1 | $803K | Buy |
51,784
+24,541
| +90% | +$527K | ﹤0.01% | 3403 |
|
|
2019
Q4 | $670K | Sell |
27,243
-57,934
| -68% | -$860K | ﹤0.01% | 4158 |
|
|
2019
Q3 | $879K | Buy |
85,177
+16,761
| +24% | +$211K | ﹤0.01% | 3785 |
|
|
2019
Q2 | $858K | Buy |
68,416
+50,680
| +286% | +$652K | ﹤0.01% | 3821 |
|
|
2019
Q1 | $219K | Sell |
17,736
-146,734
| -89% | -$1.64M | ﹤0.01% | 5009 |
|
|
2018
Q4 | $1.01M | Buy |
164,470
+125,681
| +324% | +$960K | ﹤0.01% | 3385 |
|
|
2018
Q3 | $412K | Buy |
38,789
+34,569
| +819% | +$395K | ﹤0.01% | 4511 |
|
|
2018
Q2 | $57K | Sell |
4,220
-9,361
| -69% | -$146K | ﹤0.01% | 6191 |
|
|
2018
Q1 | $241K | Sell |
13,581
-55,323
| -80% | -$934K | ﹤0.01% | 4775 |
|
|
2017
Q4 | $864K | Buy |
68,904
+32,493
| +89% | +$472K | ﹤0.01% | 3486 |
|
|
2017
Q3 | $693K | Buy |
36,411
+2,568
| +8% | +$39.2K | ﹤0.01% | 3763 |
|
|
2017
Q2 | $512K | Buy |
33,843
+26,689
| +373% | +$403K | ﹤0.01% | 3967 |
|
|
2017
Q1 | $123K | Sell |
7,154
-36,859
| -84% | -$491K | ﹤0.01% | 5052 |
|
|
2016
Q4 | $533K | Buy |
44,013
+36,443
| +481% | +$380K | ﹤0.01% | 4309 |
|
|
2016
Q3 | $74K | Sell |
7,570
-1,975
| -21% | -$18K | ﹤0.01% | 5413 |
|
|
2016
Q2 | $98K | Sell |
9,545
-25,458
| -73% | -$284K | ﹤0.01% | 5096 |
|
|
2016
Q1 | $424K | Buy |
35,003
+30,120
| +617% | +$305K | ﹤0.01% | 4303 |
|
|
2015
Q4 | $78K | Sell |
4,883
-26,142
| -84% | -$388K | ﹤0.01% | 5575 |
|
|
2015
Q3 | $398K | Buy |
31,025
+18,699
| +152% | +$377K | ﹤0.01% | 3963 |
|
|
2015
Q2 | $296K | Buy |
12,326
+638
| +5% | +$12.3K | ﹤0.01% | 4138 |
|
|
2015
Q1 | $219K | Sell |
11,688
-1,911
| -14% | -$39.5K | ﹤0.01% | 4448 |
|
|
2014
Q4 | $256K | Buy |
13,599
+8,653
| +175% | +$202K | ﹤0.01% | 4491 |
|
|
2014
Q3 | $135K | Sell |
4,946
-61,841
| -93% | -$1.92M | ﹤0.01% | 4510 |
|
|
2014
Q2 | $2.08M | Sell |
66,787
-391,934
| -85% | -$9.23M | ﹤0.01% | 2450 |
|
|
2014
Q1 | $10.4M | Buy |
458,721
+453,490
| +8,669% | +$13.7M | 0.01% | 1128 |
|
|
2013
Q4 | $109K | Buy |
5,231
+5,221
| +52,210% | +$151K | ﹤0.01% | 5191 |
|
|
2013
Q3 | $0 | Buy |
+10
| New | +$339 | ﹤0.01% | 7058 |
|
Other funds holding EPZM
Citigroup's EPZM Position: Q3 2022 in Review
Citigroup sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 461,240 shares — an estimated $678K sold.
Citigroup first reported a position in EPZM in Q3 2013 and held it in 36 quarters. The position peaked at $10.4M in Q1 2014. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Citigroup reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Citigroup sold 461,240 Epizyme, Inc shares in Q3 2022, an estimated $678K.
- Citigroup first reported a position in Epizyme, Inc in Q3 2013 and held it in 36 quarters.
- Citigroup's Epizyme, Inc position peaked at $10.4M in Q1 2014.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.